Men with fertility issues who take alpha-lipoic acid tend to have better sperm movement, count, and less DNA damage, likely because it reduces oxidative stress in reproductive tissues.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review and meta-analysis of RCTs could determine whether alpha-lipoic acid consistently improves semen parameters and live birth rates in infertile men.
A systematic review and meta-analysis of at least 10 RCTs involving men with idiopathic infertility, comparing oral alpha-lipoic acid (600–1200 mg/day) versus placebo for 12–24 weeks, with primary outcomes: sperm motility, concentration, and morphology, secondary outcomes: DNA fragmentation index and pregnancy/live birth rates.
A large RCT could determine whether alpha-lipoic acid improves semen quality and pregnancy rates in infertile men compared to placebo.
A double-blind RCT of 400 men with idiopathic infertility (semen concentration <15 million/mL), randomized to 1200 mg/day alpha-lipoic acid or placebo for 24 weeks, with primary endpoint: change in total motile sperm count, secondary endpoints: DNA fragmentation index, serum oxidative stress markers, and partner pregnancy rate at 12 months.
A prospective cohort could determine whether long-term alpha-lipoic acid use predicts improved semen parameters and time to pregnancy in infertile couples.
A prospective cohort study following 800 infertile couples for 2 years, tracking alpha-lipoic acid supplement use (dose, duration), with semen analysis every 3 months and time-to-pregnancy as primary outcome, adjusting for age, BMI, smoking, and other supplements.
A case-control study could assess whether prior alpha-lipoic acid use is less common in men with severe oligoasthenoteratozoospermia compared to those with mild or normal semen parameters.
A matched case-control study comparing 200 men with severe oligoasthenoteratozoospermia (WHO criteria) to 200 with normal semen parameters, assessing prior use of alpha-lipoic acid (≥3 months, ≥600 mg/day) over the past 2 years, adjusting for age and smoking.
A cross-sectional study could identify whether men taking alpha-lipoic acid have better semen parameters at a single point in time.
A cross-sectional survey of 600 men seeking fertility evaluation measuring current alpha-lipoic acid use and concurrent semen parameters (concentration, motility, morphology), adjusting for age, BMI, and abstinence duration.